Merck & Pfizer Win English Funding For Kidney Cancer Combo
Executive Summary
NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.